Recent Finacing
Recent Raise
GamaMabs Pharma develops monoclonal antibodies targeting AMHRII/MISRII for gynecological cancers, advancing lead candidate GM102 (3C23K) to clinical trials under exclusive LFB sublicense with academic collaborations and biomanufacturing support.
